Additionally, incorporating the use of MRI imaging of the prostate is incredibly useful, along with the other previously mentioned risk stratification tools, such as PSA and tumor grade, in determining what direction should be taken in monitoring and treating iPCa. This evidence concerns the gene KLK3 and neoplasm.